Tempest Therapeutics (TPST) Cash from Operations (2012 - 2025)
Tempest Therapeutics (TPST) posted Cash from Operations of 3574000.0 for Q4 2025, up 47.28% sequentially from 6779000.0 in Q3 2025, and up 64.78% YoY from 2168890.58 in Q4 2024.
Tempest Therapeutics (TPST) Cash from Operations (2012 - 2025) Analysis & Trends
Tempest Therapeutics has reported Cash from Operations for 14 years, with the latest figure at 3574000.0 in Q4 2025.
- Quarterly Cash from Operations rose 64.78% year-over-year to 3574000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 26820000.0 (up 18.79% YoY) and the FY2025 annual result came in at 26820000.0, up 18.79% from the prior year.
- Cash from Operations grew to 3574000.0 in Q4 2025 per TPST's latest filing, from 6779000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 127000.0 in Q2 2021 and troughed at 11789000.0 in Q3 2021.
- A 5-year average of 7211650.0 and a median of 7146500.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2022: Cash from Operations jumped 217.5% in 2021, then slumped 6725.2% in 2022.
- Over 5 years, Cash from Operations stood at 7985000.0 in 2021, then increased by 18.86% to 6479000.0 in 2022, then gained by 4.69% to 6175000.0 in 2023, then tumbled by 64.36% to 10149000.0 in 2024, then jumped by 64.78% to 3574000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 3574000.0, 6779000.0, and 8431000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.57 Mn |
| Dec 31, 2025 | -3.57 Mn |
| Sep 30, 2025 | -6.78 Mn |
| Sep 30, 2025 | -6.78 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Mar 31, 2025 | -8.04 Mn |
| Mar 31, 2025 | -8.04 Mn |
| Dec 31, 2024 | -10.15 Mn |
| Dec 31, 2024 | -10.15 Mn |
| Sep 30, 2024 | -10.18 Mn |
| Sep 30, 2024 | -10.18 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | -7.19 Mn |
| Mar 31, 2024 | -7.19 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Dec 31, 2023 | -6.18 Mn |
| Sep 30, 2023 | -6.49 Mn |
| Sep 30, 2023 | -6.49 Mn |